Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Stl 413.75 1.31
Hindalco 135.35 0.86
Tata Pow 81.55 3.61
Bhel 175.60 3.17
Ntpc Ltd 122.60 2.27
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Venus Remedies Limited
Venus Remedies Limited
Sector:Pharmaceuticals Pharmaceuticals - Pharmaceuticals - Others
BSE:526953NSE:VENUSREMBloomberg:VNR@INReuters:VENR.BO
Market Lot: 1Face Value: 10ISIN Demat: INE411B01019
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
03-APR-14 Venus Remedies has extended its footprint in Latin America with marketing authorization from meropenem from Venezuela, a USD 6 billion pharmaceutical market. 26-FEB-14 Venus Remedies, a research-based global pharmaceutical company, is all set to stamp its footprint in southeast Asia with marketing authorization for its flagship research product 'Elores' from Myanmar. The company plans to launch the drug in Myanmar by April. 01-JAN-...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Venus gets marketing nod from Venezuela for meropenem  -IRIS 03-Apr-14
Previous

More


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Dec-2013(9)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 3813.964590.974051.87
Other Income9.103.950.00
Total Income3823.064594.924051.87
Cost of goods sold2839.013428.503146.03
OPBDIT984.051166.42905.84
PAT475.37571.45500.29
Gross Block---
Equity capital114.42105.4297.42
EPS (Rs.)-54.210.00
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-2.91 - 6.05NA
Debt / Equity (x)---
Operating margin (% of OI)25.725.422.4
Net margin (% of OI)12.412.412.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
SCO 857
Cabin No 10
IInd Floor
NAC Manimajra
Chandigarh
Union Territory-160 101
PHONE
- - -
FAX
- - -
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer